PTN PALATIN TECHNOLOGIES INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 911216 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-276.9%
TTM EPS YoY-4.0%
Revenue 3-yr CAGR-61.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,354.1%
Net margin-5,261.5%
FCF margin—
EBITDA margin-5,335.2%
Returns
ROE-1,495.4%
ROA-271.7%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets57.1%
Debt / equity0.00x
Current ratio1.67x
Interest coverage-2,873.67x
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-36.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $8.83M | $0 | $4.49M | $4.85M | $1.47M |
| Cost of revenue | — | — | $97,637 | $418,470 | $217,529 |
| Gross profit | — | — | $4.39M | $4.44M | $1.25M |
| R&D expense | $12.37M | $14.90M | $22.40M | $22.63M | $21.33M |
| SG&A expense | $9.48M | $7.81M | $12.27M | $15.29M | $16.51M |
| Operating income | -$8.67M | -$17.46M | -$22.50M | -$32.46M | -$36.59M |
| Interest expense | $6,726 | $15,025 | $17,114 | $20,013 | $29,682 |
| Pretax income | — | — | — | -$32.22M | -$36.20M |
| Income tax | -$8.38M | -$17.31M | -$29.74M | -$4.67M | $0 |
| Net income | -$8.38M | -$17.31M | -$29.74M | -$24.04M | -$36.20M |
| EBITDA | -$8.61M | -$17.20M | -$22.16M | -$32.17M | -$36.46M |
| EPS (basic) | -2.96 | -32.15 | -2.02 | -2.21 | — |
| EPS (diluted) | -2.96 | -32.15 | -101.16 | — | — |
| Weighted avg. shares (diluted) | 2.83M | 538,348 | 293,951 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $7.49M | $9.53M | $9.53M | $7.99M | $29.94M |
| Short-term investments | — | — | $0 | $2.99M | $0 |
| Receivables | $300,770 | $0 | $0 | $2.92M | $1.78M |
| Inventory | — | — | $0 | $526,000 | $944,471 |
| Current assets | $8.16M | $2.92M | $9.77M | $16.32M | $34.60M |
| PP&E, net | $118,064 | $129,444 | $388,361 | $684,910 | $539,314 |
| Total assets | $8.52M | $3.27M | $10.74M | $17.94M | $36.07M |
| Current liabilities | $1.77M | $8.01M | $9.66M | $15.13M | $16.26M |
| Total liabilities | $1.84M | $8.04M | $10.85M | $19.66M | $19.80M |
| Shareholders' equity | $6.69M | -$4.78M | -$111,497 | -$1.98M | $16.27M |
| Shares outstanding | 1.78M | 929,597 | 358,532 | 11.66M | 9.27M |
| Cash flow statement | |||||
| Operating cash flow | -$13.53M | -$21.31M | -$31.46M | -$29.27M | -$29.92M |
| Capital expenditure | $51,299 | $0 | $42,526 | $433,927 | $261,374 |
| Free cash flow | -$13.58M | -$21.31M | -$31.50M | -$29.71M | -$30.18M |
| Investing cash flow | -$51,299 | $3.13M | $12.45M | -$3.43M | -$261,374 |
| Financing cash flow | $18.51M | $11.21M | $20.55M | $10.75M | $18,358 |
| Depreciation & amortization | $62,679 | $258,917 | $339,075 | $288,331 | $126,668 |
| Stock-based compensation | $1.33M | $1.38M | $1.87M | $1.67M | $2.51M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.